Dolutegravir, an effective first-line HIV drug, will soon be available as a first-line infant formula under an arrangement between several pharmaceutical firms and global health initiatives Strawberry flavor will be the new formulation and come in a tablet that dissolves in water or juice so that it can be swallowed by infants. According to the WHO, about 160,000 children are newly infected with HIV per year. When their mothers do not know that they themselves are infected, most are in Africa and infected at birth or by breastfeeding. Half of those babies will die by age 2, and 80 percent will not reach their 5th birthday without testing and care. Every year, approximately 80,000 babies and young children die of AIDS-related illnesses. Children are difficult to treat since many HIV medications taste sour, come in tablets that cannot be swallowed by infants, or are refrigerated alcohol-based syrups. Last year for around $365 a year, strawberry-flavoured "sprinkles" containing four older HIV drugs were launched that could be shaken over cereal or mixed into milk. It is important to have a drug from a new class because the increase in resistance to one drug from another class, such as fusion inhibitors or inhibitors of reverse transcriptase, also causes cross-resistance to all related drugs. Through this review, we can understand about the aids transmission and development. Our main aim is to draws readers' attention to the latest advances in HIV research in the fields of prevention, care and cure. The peoples who are interested to publish their article they can submit their manuscripts in our journal through given link: https://www.scholarscentral.org/submissions/hiv-aids-research.html